Sponsor & Developer Portfolio
Novartis Pharmaceuticals
Clinical development pipeline, platform architecture, and registered trial tracking for Novartis Pharmaceuticals vaccine candidates.
3
Candidates
3
Target Diseases
3
Linked Studies
Development Phase Distribution
Discontinued / Inactive: 1 Phase 3 Clinical Trial: 1 Phase 2 Clinical Trial: 1
Platform Technologies
Biological (unspecified platform): 2 mRNA: 1
Target Pathogens & Indications
COVID-19 Immunoglobulin A Nephropathy (IgAN) Relapsing Multiple Sclerosis
Vaccine Pipeline Candidates (3)
Detailed candidate profiles, clinical phases, target indications, and anticipated milestones.
Discontinued / Inactive
ctgov-mrna-covid-19-vaccine-novartis-pharmaceuticals
mRNA COVID-19 vaccine
Target: COVID-19
Platform: mRNA
Key Milestone: Primary completion (most advanced trial): 2023-04-14 (registry estimate)
Phase 2 Clinical Trial
ctgov-zigakibart-novartis-pharmaceuticals
zigakibart
Target: Immunoglobulin A Nephropathy (IgAN)
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2030-07-12 (registry estimate)
Phase 3 Clinical Trial
ctgov-ofatumumab-novartis-pharmaceuticals
Ofatumumab
Target: Relapsing Multiple Sclerosis
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2028-09-30 (registry estimate)
Explore Other Vaccine Developers & Sponsors
Compare pipeline volume, phase progression, and modalities across global biopharmaceutical manufacturers.